Your browser doesn't support javascript.
loading
Early Palliative Care in Acute Myeloid Leukemia.
Potenza, Leonardo; Borelli, Eleonora; Bigi, Sarah; Giusti, Davide; Longo, Giuseppe; Odejide, Oreofe; Porro, Carlo Adolfo; Zimmermann, Camilla; Efficace, Fabio; Bruera, Eduardo; Luppi, Mario; Bandieri, Elena.
Afiliação
  • Potenza L; Hematology Unit and Chair, Azienda Ospedaliera Universitaria di Modena and Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.
  • Borelli E; Hematology Unit and Chair, Azienda Ospedaliera Universitaria di Modena and Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.
  • Bigi S; Department of Linguistic Sciences and Foreign Literatures, Catholic University of the Sacred Heart, 20123 Milan, Italy.
  • Giusti D; Hematology Unit and Chair, Azienda Ospedaliera Universitaria di Modena and Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.
  • Longo G; Oncological Medicine Unit, Azienda Ospedaliera Universitaria di Modena, 41125 Modena, Italy.
  • Odejide O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Porro CA; Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.
  • Zimmermann C; Center for Neuroscience and Neurotechnology, University of Modena and Reggio Emilia, 41125 Modena, Italy.
  • Efficace F; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5B 2M9, Canada.
  • Bruera E; Division of Palliative Care, University of Toronto, Toronto, ON M5S 1A4, Canada.
  • Luppi M; Italian Group for Adult Hematologic Diseases (GIMEMA), Health Outcomes Research Unit, 00182 Rome, Italy.
  • Bandieri E; Palliative Care & Rehabilitation Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Cancers (Basel) ; 14(3)2022 Jan 18.
Article em En | MEDLINE | ID: mdl-35158746
ABSTRACT

BACKGROUND:

Several novel targeted therapies seem to improve the outcome of acute myeloid leukemia (AML) patients. Nonetheless, the 5-year survival rate remains below 40%, and the trajectory of the disease remains physically and emotionally challenging, with little time to make relevant decisions. For patients with advanced solid tumors, the integration of early palliative care (EPC) with standard oncologic care a few weeks after diagnosis has demonstrated several benefits. However, this model is underutilized in patients with hematologic malignancies.

METHODS:

In this article, we analyze the palliative care (PC) needs of AML patients, examine the operational aspects of an integrated model, and review the evidence in favor of EPC integration in the AML course.

RESULTS:

AML patients have a high burden of physical and psychological symptoms and high use of avoidant coping strategies. Emerging studies, including a phase III randomized controlled trial, have reported that EPC is feasible for inpatients and outpatients, improves quality of life (QoL), promotes adaptive coping, reduces psychological symptoms, and enhances the quality of end-of-life care.

CONCLUSIONS:

EPC should become the new standard of care for AML patients. However, this raises issues about the urgent development of adequate programs of education to increase timely access to PC.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article